Profile picture

Professor Peter Libby

Mass General Brigham, Boston (United States of America)
Membership: FESC Member
Follow
Biography
Peter Libby, MD, is a cardiovascular specialist at Brigham and Women’s Hospital in Boston, Massachusetts, and holds the Mallinckrodt Professorship of Medicine at Harvard Medical School. He actively practices general and preventive cardiology and vascular medicine. His current major research focus is the role of inflammation in vascular diseases such as atherosclerosis. He conducts basic and translational research in cardiovascular diseases focusing on inflammatory aspects and vascular biology. Dr. Libby has a particular devotion to translate his basic laboratory studies to pilot and then large-scale clinical cardiovascular outcome trials. Dr. Libby has received numerous awards and recognitions for his research accomplishments, and has received a number of lifetime achievement awards from various organizations.
Logo ESC

Contributor content

Late-Breaking Clinical Science: inflammation and immune biomarkers in cardiovascular risk prediction
Session
Late-Breaking Clinical Science: inflammation and immune biomarkers in cardiovascular risk prediction
29 August 2025
The EHJ’s year in heart failure, ischaemic heart disease and acute cardiovascular care, dyslipidaemias
Session
The EHJ’s year in heart failure, ischaemic heart disease and acute cardiovascular care, dyslipidaemias
31 August 2024
Evolution of coronary artery disease diagnosis ... from stenosis to inflammation
Session
Evolution of coronary artery disease diagnosis ... from stenosis to inflammation
30 August 2024
Smaller trials, trial updates, and other studies on inflammation and immunity in cardiovascular disease
Session
Smaller trials, trial updates, and other studies on inflammation and immunity in cardiovascular disease
30 August 2024
Inflammation as key driver of vascular dysfunction
Session
Inflammation as key driver of vascular dysfunction
28 August 2023
Improving the management of patients with atherosclerotic cardiovascular disease: the evolving role of icosapent ethyl
Session
Improving the management of patients with atherosclerotic cardiovascular disease: the evolving role of icosapent ethyl
27 August 2023
Vascular disease and perturbed lipid metabolism
Session
Vascular disease and perturbed lipid metabolism
26 August 2023
Inflammation in atherosclerotic cardiovascular disease (ASCVD): the spark before the fire?
Session
Inflammation in atherosclerotic cardiovascular disease (ASCVD): the spark before the fire?
27 August 2022
The EHJ’s Year in Cardiovascular Medicine 2020: heart failure, valvular heart disease, imaging
Session
The EHJ’s Year in Cardiovascular Medicine 2020: heart failure, valvular heart disease, imaging
29 August 2021
Tackling residual risk beyond LDL-c therapy: The emerging role of EPA & triglycerides
Session
Tackling residual risk beyond LDL-c therapy: The emerging role of EPA & triglycerides
29 August 2021

ESC 365 is supported by